{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:05:33Z","timestamp":1791353133151,"version":"4.3.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,7,13]],"date-time":"2013-07-13T00:00:00Z","timestamp":1373673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s11307-013-0659-2","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T16:26:43Z","timestamp":1373646403000},"page":"118-126","source":"Crossref","is-referenced-by-count":16,"title":["2-[18F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models"],"prefix":"10.1007","volume":"16","author":[{"given":"Martine","family":"Dhilly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Guillouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"patin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Fillesoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Gourand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Galateau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dumontet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Leporrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Barr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,13]]},"reference":[{"key":"659_CR1","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","volume":"110","author":"P Seam","year":"2007","unstructured":"Seam P, Juweid ME, Cheson BD (2007) The role of FDG-PET scans in patients with lymphoma. Blood 110:3507\u20133516","journal-title":"Blood"},{"key":"659_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rcl.2008.04.002","volume":"46","author":"H Sch\u00f6der","year":"2008","unstructured":"Sch\u00f6der H, Moskowitz C (2008) PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin N Am 46:225\u201342","journal-title":"Radiol Clin N Am"},{"key":"659_CR3","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","volume":"101","author":"R Elstrom","year":"2003","unstructured":"Elstrom R, Guan L, Baker G et al (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875\u20133876","journal-title":"Blood"},{"key":"659_CR4","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2005.12.072","volume":"23","author":"H Sch\u00f6der","year":"2005","unstructured":"Sch\u00f6der H, Noy A, G\u00f6nen M et al (2005) Intensity of 18Fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin\u2019s lymphomas. J Clin Oncol 23:4643\u20134651","journal-title":"J Clin Oncol"},{"key":"659_CR5","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"N Tsukamoto","year":"2007","unstructured":"Tsukamoto N, Kojima M, Hasegawa M et al (2007) The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma. Relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652\u2013659","journal-title":"Cancer"},{"key":"659_CR6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000070290","volume":"64","author":"M Hoffmann","year":"2003","unstructured":"Hoffmann M, Kletter K, Becherer A et al (2003) 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 64:336\u2013340","journal-title":"Oncology"},{"key":"659_CR7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3816\/CLM.2008.n.019","volume":"8","author":"S Gill","year":"2008","unstructured":"Gill S, Wolf M, Prince HM et al (2008) [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 8:159\u2013165","journal-title":"Clin Lymphoma Myeloma"},{"key":"659_CR8","doi-asserted-by":"crossref","first-page":"11055","DOI":"10.1158\/0008-5472.CAN-06-1955","volume":"66","author":"AK Buck","year":"2006","unstructured":"Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G et al (2006) Molecular imaging of proliferation in malignant lymphoma. Cancer Res 66:11055\u201311061","journal-title":"Cancer Res"},{"issue":"14","key":"659_CR9","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/molecules14031183","volume":"23","author":"T Robak","year":"2009","unstructured":"Robak T, Korycka A, Lech-Maranda E, Robak P (2009) Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 23(14):1183\u20131226","journal-title":"Molecules"},{"key":"659_CR10","first-page":"83","volume":"38","author":"MJ Keating","year":"1996","unstructured":"Keating MJ, O\u2019Brien S, McLaughlin P et al (1996) Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 38:83\u201391","journal-title":"Hematol Cell Ther"},{"key":"659_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.thj.6200387","volume":"5","author":"M Leporrier","year":"2004","unstructured":"Leporrier M (2004) Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Hematol J 5:10\u201319","journal-title":"Hematol J"},{"key":"659_CR12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/15257770.2011.603716","volume":"30","author":"S Henrich","year":"2011","unstructured":"Henrich S, Mactier S, Best G et al (2011) Fludarabine nucleoside modulates nuclear \u201csurvival and death\u201d proteins in resistant chronic lymphocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids 30:1181\u20131189","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"659_CR13","first-page":"700","volume":"47","author":"JR Barrueco","year":"1987","unstructured":"Barrueco JR, Jacobsen DM, Chang CH et al (1987) Proposed mechanism of therapeutic selectivity for 9-\u03b2-d-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res 47:700\u2013706","journal-title":"Cancer Res"},{"key":"659_CR14","first-page":"6201","volume":"54","author":"V Gr\u00e9goire","year":"1994","unstructured":"Gr\u00e9goire V, Van NT, Stephens LC et al (1994) The role of fludarabine-induced apoptosis and cell cycle synchronization in enhanced murine tumor radiation response in vivo. Cancer Res 54:6201\u20136209","journal-title":"Cancer Res"},{"key":"659_CR15","first-page":"2","volume":"20","author":"W Plunkett","year":"1993","unstructured":"Plunkett W, Gandhi V, Huang P et al (1993) Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 20:2\u201312","journal-title":"Semin Oncol"},{"key":"659_CR16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-200241020-00002","volume":"41","author":"V Gandhi","year":"2002","unstructured":"Gandhi V, Plunkett W (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93\u2013103","journal-title":"Clin Pharmacokinet"},{"key":"659_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00262285","volume":"18","author":"L Danhauser","year":"1986","unstructured":"Danhauser L, Plunkett W, Keating M, Cabanillas F (1986) 9-beta-d-Arabinofuranosyl-2-fluoroadenine 5\u2032-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18:145\u2013152","journal-title":"Cancer Chemother Pharmacol"},{"key":"659_CR18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1021\/ml100055m","volume":"1","author":"P Marchand","year":"2010","unstructured":"Marchand P, Lorilleux C, Gilbert G et al (2010) Efficient radiosynthesis of 2-[18F]fluoroadenosine: a new route to 2-[18F]fluoropurine nucleosides. ACS Med Chem Lett 1:240\u2013243","journal-title":"ACS Med Chem Lett"},{"key":"659_CR19","doi-asserted-by":"crossref","unstructured":"Guillouet S, Patin D, Tirel O et al. (2013) Fully automated radiosynthesis of 2-[18F]fludarabine for PET imaging of low-grade lymphoma. Mol Imaging Biol (in press)","DOI":"10.1007\/s11307-013-0657-4"},{"key":"659_CR20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-08-1685","volume":"15","author":"S Dalle","year":"2009","unstructured":"Dalle S, Dupire S, Brunet-Manquat S et al (2009) In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res 15:851\u2013857","journal-title":"Clin Cancer Res"},{"key":"659_CR21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2967\/jnumed.108.056374","volume":"50","author":"Q Bao","year":"2009","unstructured":"Bao Q, Newport D, Chen M et al (2009) Performance evaluation of the Inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med 50:401\u2013408","journal-title":"J Nucl Med"},{"key":"659_CR22","first-page":"180","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"HK M\u00fcller-Hermelink","year":"2008","unstructured":"M\u00fcller-Hermelink HK, Montserrat E, Catovsky D et al (2008) Chronic lymphocytic leukaemia\/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 180\u2013182","edition":"4"},{"issue":"3","key":"659_CR23","first-page":"248","volume":"16","author":"AS Kirschner","year":"1975","unstructured":"Kirschner AS, Ice RD, Beierwaltes WH (1975) Radiation dosimetry of 131I-19-iodocholesterol: the pitfalls of using tissue concentration data, the author\u2019s reply. J Nucl Med 16(3):248\u2013249","journal-title":"J Nucl Med"},{"key":"659_CR24","first-page":"1023","volume":"46","author":"MG Stabin","year":"2005","unstructured":"Stabin MG, Sparks RB, Crowe E (2005) OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023\u20131027","journal-title":"J Nucl Med"},{"key":"659_CR25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2009-09-244947","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW (2010) PET positive, PET negative, or PET peeve? Blood 115:752\u2013753","journal-title":"Blood"},{"key":"659_CR26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/cncr.21967","volume":"107","author":"M Karam","year":"2006","unstructured":"Karam M, Novak L, Cyriac J et al (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107:175\u2013183","journal-title":"Cancer"},{"key":"659_CR27","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079\u20134088","journal-title":"J Clin Oncol"},{"key":"659_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Rai K, Peterson BL et al (2005) Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49\u201353","journal-title":"Blood"},{"key":"659_CR29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","volume":"107","author":"BF Eichhorst","year":"2006","unstructured":"Eichhorst BF, Busch R, Hopfinger G et al (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885\u2013891","journal-title":"Blood"},{"key":"659_CR30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","volume":"370","author":"D Catovsky","year":"2007","unstructured":"Catovsky D, Richards S, Matutes E et al (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370:230\u2013239","journal-title":"Lancet"},{"key":"659_CR31","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164\u20131174","journal-title":"Lancet"},{"issue":"2","key":"659_CR32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.1996.14.2.514","volume":"14","author":"P Solal-C\u00e9ligny","year":"1996","unstructured":"Solal-C\u00e9ligny P, Brice P, Brousse N et al (1996) Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 14(2):514\u2013519","journal-title":"J Clin Oncol"},{"key":"659_CR33","first-page":"108","volume":"75","author":"CH Ladel","year":"1991","unstructured":"Ladel CH, Bamberger U, P\u00fcschner H (1991) Histological and cytofluorometric investigations of immunodeficient CB17 SCID\/SCID mice. Verh Dtsch Ges Pathol 75:108\u2013113","journal-title":"Verh Dtsch Ges Pathol"},{"key":"659_CR34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s002590050257","volume":"25","author":"HM Deloar","year":"1998","unstructured":"Deloar HM, Fujiwara T, Shidahara M et al (1998) Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-d-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med 25:565\u201357","journal-title":"Eur J Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-013-0659-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-013-0659-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-013-0659-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T03:32:55Z","timestamp":1563420775000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-013-0659-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,13]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1007\/s11307-013-0659-2","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,13]]}}}